Drug Type Bispecific antibody |
Synonyms Anti-CCR8xCTLA-4 bispecific antibody (Biotheus), PM 1092, PM1092 |
Target |
Action inhibitors |
Mechanism CCR8 inhibitor(C-C motif chemokine receptor 8 inhibitors), CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | China | 06 Dec 2023 |






